These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 31535761)

  • 1. Age and gender influence on HIDRAdisk outcomes in adalimumab-treated hidradenitis suppurativa patients.
    Fabbrocini G; Marasca C; Megna M; Peris K;
    J Eur Acad Dermatol Venereol; 2019 Oct; 33 Suppl 6():25-27. PubMed ID: 31535761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa.
    Peris K; Lo Schiavo A; Fabbrocini G; Dini V; Patrizi A; Fusano M; Bianchi L; Guanziroli E; Guarneri C; Parodi A; Bertoldi A; Musumeci ML; Offidani A; Rongioletti F; Pistone G; Malara G; Potenza C; Casari A; Franchi C; Ardigò M; Cusano F; Stingeni L; Amerio P; Mancini LL; Prignano F; Deboli T; Gualberti G; Saragaglia V; Bettoli V
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):766-773. PubMed ID: 30633405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hidradenitis Suppurativa in a Large Cohort of Italian Patients: Evaluation of the Burden of Disease.
    Fabbrocini G; Ruina G; Giovanardi G; Dini V; Raone B; Venturini M; Caposiena Caro RD; Veraldi S; Cannavò SP; Merlo G; Bertoldi AM; Fiorentini F; Molinelli E; Atzori L; Bongiorno MR; Lo Re M; Skroza N; Lasagni C; Franchi C; Ardigò M; Di Costanzo L; Stingeni L; Amerio P; Sanna F; Pescitelli L; Broganelli P; De Cupis C; Gualberti G; Saragaglia V; Argenziano G
    Dermatology; 2022; 238(3):487-497. PubMed ID: 34474409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab versus Rifampicin Plus Clindamycin for the Treatment of Moderate to Severe Hidradenitis Suppurativa: A Retrospective Study.
    Marasca C; Annunziata MC; Villani A; Volpe S; Marasca D; Fabbrocini G
    J Drugs Dermatol; 2019 May; 18(5):437-438. PubMed ID: 31141853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
    Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T
    J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
    Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
    Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
    Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
    J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab.
    Caposiena Caro RD; Cannizzaro MV; Tartaglia C; Bianchi L
    Clin Exp Dermatol; 2020 Jun; 45(4):438-444. PubMed ID: 31630436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement in Hidradenitis Suppurativa and quality of life in patients treated with adalimumab: Real-world results from the HARMONY Study.
    Hafner A; Ghislain PD; Kovács R; Batchelor R; Katoulis AC; Kirby B; Banayan H; Schonbrun M
    J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):2277-2284. PubMed ID: 34320249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With Adalimumab.
    Gulliver W; Alavi A; Wiseman MC; Gooderham MJ; Rao J; Shayesteh Alam M; Papp KA; Desjardins O; Jean C
    J Cutan Med Surg; 2022; 26(4):361-370. PubMed ID: 35322692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the psychological burden of patients with hidradenitis suppurativa.
    Frings VG; Bauer B; Glöditzsch M; Goebeler M; Presser D
    Eur J Dermatol; 2019 Jun; 29(3):294-301. PubMed ID: 31145081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: Clinical and ultrasound observations.
    Caposiena Caro RD; Cannizzaro MV; Botti E; Di Raimondo C; Di Matteo E; Gaziano R; Bianchi L
    J Am Acad Dermatol; 2019 May; 80(5):1314-1321. PubMed ID: 30502416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa.
    Chiricozzi A; Faleri S; Franceschini C; Caro RD; Chimenti S; Bianchi L
    Wounds; 2015 Oct; 27(10):258-64. PubMed ID: 26479209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa.
    van Rappard DC; Leenarts MF; Meijerink-van 't Oost L; Mekkes JR
    J Dermatolog Treat; 2012 Aug; 23(4):284-9. PubMed ID: 21756155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Broad-Spectrum Impact of Hidradenitis Suppurativa on Quality of Life: A Comparison with Psoriasis.
    Sampogna F; Fania L; Mazzanti C; Caggiati A; Pallotta S; Panebianco A; Mastroeni S; Didona B; Pintori G; Abeni D
    Dermatology; 2019; 235(4):308-314. PubMed ID: 31121589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.
    Miller I; Lynggaard CD; Lophaven S; Zachariae C; Dufour DN; Jemec GB
    Br J Dermatol; 2011 Aug; 165(2):391-8. PubMed ID: 21457202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of Life in Hidradenitis Suppurativa: An Update.
    Chernyshov PV; Finlay AY; Tomas-Aragones L; Poot F; Sampogna F; Marron SE; Zemskov SV; Abeni D; Tzellos T; Szepietowski JC; Zouboulis CC
    Int J Environ Res Public Health; 2021 Jun; 18(11):. PubMed ID: 34204126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US.
    Ingram JR; Bettoli V; Espy JI; Kokolakis G; Martorell A; Villani AP; Wallinger H; Coak E; Kasparek T; Muscianisi E; Richardson C; Kimball AB
    J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):1597-1605. PubMed ID: 35445469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa.
    Zouboulis CC; Hansen H; Caposiena Caro RD; Damiani G; Delorme I; Pascual JC; Reguiai Z; Trigoni A; Vilarrasa E; Alfageme Roldán F
    Dermatology; 2020; 236(1):25-30. PubMed ID: 31630144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa.
    Leslie KS; Tripathi SV; Nguyen TV; Pauli M; Rosenblum MD
    J Am Acad Dermatol; 2014 Feb; 70(2):243-51. PubMed ID: 24314876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.